Background Berotralstat (BCX7353) is an oral, once‐daily inhibitor of plasma kallikrein
recently approved for prevention of angioedema attacks in adults and adolescents with …

Background Berotralstat (BCX7353) is an oral, once-daily inhibitor of plasma kallikrein in
development for the prophylaxis of hereditary angioedema (HAE) attacks. Objective Our aim …

Background Berotralstat is a first-line, once-daily oral plasma kallikrein inhibitor approved for
prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years or older. Objective …

Background Berotralstat (BCX7353) is a recently approved, oral, once-daily kallikrein
inhibitor for hereditary angioedema (HAE) prophylaxis. In the APeX-2 trial, berotralstat …

Background: Hereditary angioedema (HAE) is a rare genetic disorder characterized by
unpredictable and potentially life-threatening episodes of swelling in various parts of the …

Introduction Hereditary angioedema due to C1-inhibitor deficiency (C1-INH-HAE) imposes a
significant disease burden on patients and their families. Unpredictable episodes of …

Background With no approved treatments in Japan for the prevention of hereditary
angioedema (HAE) attacks, there is a significant unmet need for long‐term prophylactic …

Background Hereditary angioedema (HAE) with C1‐inhibitor deficiency (HAE‐C1‐INH) is
characterized by recurrent, debilitating episodes of swelling. Sebetralstat, an investigational …

Background Guidelines recommend effective on-demand therapy for all individuals with
hereditary angioedema. We aimed to assess the novel oral plasma kallikrein inhibitor …

Hereditary angioedema (HAE) and acquired C1-inhibitor deficiency (AAE-C1-INH) are
orphan diseases. Berotralstat is a recently licensed long-term prophylaxis (LTP) and the first …